POMGnT1 Mutations in Congenital Muscular Dystrophy (2024)

Background Muscle-eye-brain disease is a congenital muscular dystrophy with eye and brain involvement due to POMGnT1 mutations.

Objective To describe the clinical and molecular features of 3 Italian patients with POMGnT1 mutations.

Design Case reports.

Patients One patient had muscle and brain abnormalities without eye involvement. Two patients had a classic muscle-eye-brain disease phenotype with different levels of clinical severity.

Results Brain magnetic resonance imaging showed cortical malformation and posterior fossa involvement. Immunofluorescence for glycosylated α-dystroglycan performed on muscle biopsy specimens demonstrated an absent signal in 1 patient and reduced staining in 2 patients. Molecular analysis identified 5 mutations, 2 of which are novel.

Conclusion This article adds to what is known about the genotype-phenotype correlation and expands our awareness of the clinical spectrum associated with POMGnT1 mutations.

Congenital muscular dystrophies (CMDs) caused by mutations in genes encoding proven or putative glycosyltransferases, or α-dystroglycanopathies, are characterized by abnormally glycosylated dystroglycan.¹ This group includes Walker-Warburg syndrome caused by mutations in POMT1² and POMT2³; muscle-eye-brain disease (MEB) caused by mutations in POMGnT1⁴; f*ckuyama CMD caused by mutations in f*ckutin⁵; CMD type 1C caused by mutations in FKRP⁶; and CMD type 1D secondary to mutations in LARGE.⁷

Muscle-eye-brain disease (Online Mendelian Inheritance in Man 253280) is an autosomal recessive disorder characterized by a combination of CMD, ocular involvement, structural brain changes, and mental retardation.⁸ The gene responsible for MEB is glycosyltransferase O-mannose β-1,2-N-acetylglucosaminyltransferase (POMGnT1), encoding a protein that catalyzes the transfer of N-acetylglucosamine to O-mannose of glycoproteins, including dystroglycan. Twenty-four different mutations in POMGnT1 have been identified in patients with MEB⁹; however, the genotype-phenotype correlation remains unclear.

We report the clinical and molecular features of 3 Italian patients with CMDs harboring POMGnT1 mutations and showing different levels of clinical severity. The clinical and neuroradiological findings for the 3 patients are summarized in the Table.

Patient 1 had had onset of symptoms at age 22 months. At age 30 years, she had severe mental retardation and epilepsy without evidence of ocular involvement on eye examination or electroretinography. Because of slightly elevated serum creatine kinase levels (range, 300-400 U/L; reference level, <150 U/L), she had undergone 2 muscle biopsies, at 5 and 28 years of age. The latest neurological examination showed brisk tendon reflexes, normal muscle strength with manual muscle testing, and pseudohypertrophic appearance of the leg and thigh muscles.

Patient 2 and patient 3 manifested ocular abnormalities and muscular hypotonia at birth and at 2 months of age, respectively. Epileptic seizures occurred only in patient 2, at age 10 months. Patient 2 at age 6 years had moderate mental retardation, and patient 3 at age 7 had severe mental retardation. Serum creatine kinase levels were elevated in both patients (1500 U/L in patient 2 and 1000 U/L in patient 3).

After obtaining informed consent, muscle biopsy specimens were obtained for diagnostic purposes and were processed according to standard histological and immunohistochemical techniques. Immunohistochemical analysis was performed using the following monoclonal antibodies: antimouse α-dystroglycan (VIA4-1; Upstate Biotechnology, Lake Placid, NY), antilaminin α2 chain (merosin) (5H2; Chemicon, Milano, Italy), and antilaminin 2 α2 chain (4H8-2; ALEXIS Biochemicals, Lausen, Switzerland).

DNA was obtained from peripheral lymphocytes using standard techniques. The entire coding region and the exon-intron boundaries of POMGnT1 were amplified by polymerase chain reaction using a set of intronic primer pairs. Total RNA was prepared from a muscle biopsy sample of patient 2 using a kit from Qiagen (Qiagen Total RNA; Qiagen Inc, Studio City, Calif), and reverse transcriptase–polymerase chain reaction was performed using oligo-dT priming. Polymerase chain reaction products were purified and directly sequenced using a multi-color fluorescence-based DNA analysis system (ABI Prism 3100 Genetic Analyzer; Applied Biosystems, Foster City, Calif).

Clinical and brain magnetic resonance imaging findings are summarized in the Table and in Figure 1 and Figure 2. Muscle biopsy specimens showed mild fiber diameter variability, a slightly increased number of fibers with central nuclei, and an absence of necrosis and fibrosis in patient 1; specimens showed marked fiber diameter variability and signs of necrosis and fibrosis in patient 2 and patient 3. Immunofluorescence for glycosylated α-dystroglycan showed an absent signal in patient 2, markedly reduced staining in patient 1, and reduced staining in patient 3. Merosin deficiency was observed in all patients, probably a secondary manifestation as previously reported.¹⁰

Five mutations, 2 of which are novel, were identified. Patient 1 carried a hom*ozygous glutamine to arginine transition (c932G>A) in exon 10, with a predicted effect of pArg311Gln. Patient 2 was compound heterozygous for a novel cytosine to thymine transition (c931C>T) in exon 10, changing an arginine to a stop (pArg311Stop) and for an arginine to glutamine transition at the splice acceptor site of intron 15 (c1285-2A>G). To verify its pathogenic role, we amplified the complementary DNA comprising the region. This mutation produces 3 different messenger RNA (mRNA) isoforms, the first retaining the entire intron 15 with an inframe insertion of 81 nucleotides, the second skipping exon 16, and the third resulting in residual correct splicing as observed in healthy subjects. In patient 3, we identified a novel cytosine to glutamine transversion in exon 7 (c594C>G, pSer198Arg) and a glutamine to arginine transition (c1469G>A) in exon 17 (c1469G>A, pCys490Tyr) (Figure 2). POMT1 and POMT2 gene sequencing in patient 1 revealed no alterations. The identified novel mutations met accepted consensus guidelines for pathogenic variants, including a high degree of conservation of the affected residue among different species, and were absent from a large group of control chromosomes (from 192 white healthy control subjects).^11,12

More than 30 subjects with mutations in POMGnT1 have been identified worldwide, and the clinical spectrum is broad, ranging from the classic MEB phenotype to a more severe clinical picture, with features consistent with Walker-Warburg syndrome or f*ckuyama CMD.¹¹ To our knowledge, no mutational hot spot has been identified, and missense and nonsense mutations are distributed along the entire gene. Although the genotype-phenotype correlation remains unclear, mutations near the 5′ terminus are associated with a more severe clinical picture than those near the 3′ terminus.⁸

We identified 5 POMGnT1 mutations in 3 Italian patients, 1 patient with an unusual phenotype characterized by CMD and brain involvement only (MEB-minus) and 2 patients with MEB phenotypes of different levels of severity. All 3 patients showed peculiar findings on magnetic resonance imaging of α-dystroglycanopathies, characterized by cerebral neuronal migration disorder and posterior fossa involvement, although their clinical presentation varied. The phenotype of patient 1 is unusual because of the absence of ocular abnormalities, only slightly elevated serum creatine kinase levels, and the prominent brain involvement, characterized on magnetic resonance imaging by cortical dysplasia and hypoplasia of the brainstem. The clinical pattern is also atypical for MEB because the patient is still able to walk in the third decade of life, and her prominent symptoms are mental deficiency and epilepsy, without muscle weakness. She carries a hom*ozygous mutation (pArg311Gln), which has been detected in 2 heterozygous siblings with classic MEB showing hydrocephalus and early-onset glaucoma.¹³

The mild MEB phenotype in patient 2 is the result of 2 severe mutations (a null allele caused by a new nonsense variant in exon 10 [pArg311Stop] and a previously reported alteration in the conserved acceptor splice site of intron 15).⁹ The residual presence of normal mRNA encoding a normal protein could explain the lesser severity of the phenotype in this patient. The identification of mutations involving Arg311 in patient 1 and patient 2, as well as in 2 other patients described in the literature,¹³ suggests the presence of a mutational hot spot. The residue Arg311 is located in the highly conserved N-acetylglucosaminyltransferase catalytic domain of POMGnT1¹³ and is critical for the binding of uridine diphosphate–N–acetylglucosamine and the manganese ion.

Patient 3, who had severe MEB, carried 2 apparently mild missense mutations, a novel pSer198Arg in the stem domain and a previously reported pCys490Tyr.⁹ The pSer198 mutation is evolutionarily conserved and results in a change from an uncharged polar to a positively charged amino acid. Unlike many other glycotransferases, the loss of the stem domain or single amino acid substitutions in the stem domain of POMGnT1 have been shown to abolish the activity of the membrane-bound form of POMGnT1.¹⁴ Missense mutations in the stem domain may diminish retention of the protein in the Golgi apparatus or may trigger a conformational change that inhibits the accessibility of the acceptor or donor substrate in the catalytic domain.

This study increases our knowledge of the genotype-phenotype correlation and expands our awareness of the clinical spectrum associated with POMGnT1 mutations. Furthermore, magnetic resonance imaging findings appear to be crucial in addressing appropriate genetic studies in CMDs.

Correspondence: Roberta Biancheri, MD, Muscular and Neurodegenerative Disease Unit, Department of Neuroscience and Rehabilitation, University of Genova, Largo G. Gaslini 5, I-16147 Genova, Italy (roberta@biancheri.com).

Accepted for Publication: March 8, 2006.

Author Contributions:Study concept and design: Biancheri, Bertini, Cassandrini, Zara, Santorelli, and Bruno. Acquisition of data: Falace, Pedemonte, D’Amico, Scapolan, Bergamino, Petrini, Broda, Manfredi, and Zara. Analysis and interpretation of data: Biancheri, Rossi, Zara, Minetti, and Bruno. Drafting of the manuscript: Biancheri, Pedemonte, D’Amico, Santorelli, and Bruno. Critical revision of the manuscript for important intellectual content: Bertini, Rossi, Scapolan, Cassandrini, Broda, Manfredi, Zara, Santorelli, and Minetti. Obtained funding: Minetti and Bruno. Administrative, technical, and material support: Rossi, Scapolan, and Bergamino. Study supervision: Biancheri, Santorelli, and Bruno.

Funding/Support: This study was supported by telethon project GUP030558 on congential muscular dystrophy with mental retardation.

Acknowledgment: We thank Kim H. Wessling, MD, for reviewing the manuscript.